[go: up one dir, main page]

AR072442A1 - Metodo para la terapia del cancer, uso, kit - Google Patents

Metodo para la terapia del cancer, uso, kit

Info

Publication number
AR072442A1
AR072442A1 ARP090100051A ARP090100051A AR072442A1 AR 072442 A1 AR072442 A1 AR 072442A1 AR P090100051 A ARP090100051 A AR P090100051A AR P090100051 A ARP090100051 A AR P090100051A AR 072442 A1 AR072442 A1 AR 072442A1
Authority
AR
Argentina
Prior art keywords
kit
cancer therapy
treatment
cancer
medicament
Prior art date
Application number
ARP090100051A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40365425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072442(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR072442A1 publication Critical patent/AR072442A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: El uso del compuesto de formula (1) o una sal farmacéuticamente aceptable del mismo, para la fabricacion de un medicamento destinado al tratamiento del cáncer, en particular de tumores solidos. Reivindicacion 16: Un método para la fabricacion de un medicamento destinado al tratamiento del cáncer, en particular de tumores solidos, caracterizado porque se emplea el compuesto de la formula (1) en una cantidad terapéuticamente eficaz. Reivindicacion 34: Los métodos y usos segun la reivindicacion 33 para el tratamiento de cáncer pancreático.
ARP090100051A 2008-01-11 2009-01-08 Metodo para la terapia del cancer, uso, kit AR072442A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2044708P 2008-01-11 2008-01-11

Publications (1)

Publication Number Publication Date
AR072442A1 true AR072442A1 (es) 2010-09-01

Family

ID=40365425

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100051A AR072442A1 (es) 2008-01-11 2009-01-08 Metodo para la terapia del cancer, uso, kit

Country Status (17)

Country Link
US (1) US20090181944A1 (es)
EP (1) EP2244713A1 (es)
JP (3) JP5612482B2 (es)
KR (2) KR20140007979A (es)
CN (1) CN101909633B (es)
AR (1) AR072442A1 (es)
AU (1) AU2009203776A1 (es)
BR (1) BRPI0906831A2 (es)
CA (1) CA2710913A1 (es)
CL (1) CL2009000040A1 (es)
CR (1) CR11510A (es)
IL (1) IL206361A0 (es)
MA (1) MA33076B1 (es)
RU (1) RU2010133489A (es)
TW (1) TW200936139A (es)
WO (1) WO2009087130A1 (es)
ZA (1) ZA201004859B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669693C (en) 2006-11-15 2018-06-12 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
CA2743436C (en) 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
US8309299B2 (en) * 2010-05-19 2012-11-13 Hoffmann-La Roche Inc. Combination therapy and method for assessing resistance to treatment
KR101330184B1 (ko) 2010-10-15 2013-11-15 성균관대학교산학협력단 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물
WO2012050370A2 (ko) * 2010-10-15 2012-04-19 성균관대학교산학협력단 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물
US20120114638A1 (en) * 2010-11-08 2012-05-10 John Boylan Combination therapy
US20120225860A1 (en) * 2011-03-02 2012-09-06 John Frederick Boylan Method for administration of a gamma secretase inhibitor
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
JO3148B1 (ar) 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
US9249157B2 (en) 2012-09-21 2016-02-02 Bristol-Myers Squibb Company Tricyclic heterocycle compounds
CN104854094A (zh) 2012-09-21 2015-08-19 百时美施贵宝公司 氟烷基二苯并二氮杂*酮化合物
US9242940B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
US9273075B2 (en) 2012-09-21 2016-03-01 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
CN105308030A (zh) 2012-09-21 2016-02-03 百时美施贵宝公司 烷基、氟烷基-1,4-苯并二氮杂*酮化合物
CN104797569A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 取代的1,5-苯并二氮杂*酮化合物
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
WO2014047397A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors
JP2016515625A (ja) * 2013-04-04 2016-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 増殖性疾患を治療するための併用療法
WO2015095116A1 (en) * 2013-12-17 2015-06-25 Rush University Medical Center Compositions and methods for treating diabetic nephropathy
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
WO2016069906A1 (en) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
KR20180117628A (ko) 2016-01-29 2018-10-29 매사추세츠 아이 앤드 이어 인퍼머리 내이 지지 세포의 확장 및 분화 및 그의 사용 방법
WO2017180385A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
KR102362222B1 (ko) 2016-05-16 2022-02-11 더 제너럴 하스피탈 코포레이션 폐 상피 공학에서 인간 기도 줄기 세포
JP7194022B2 (ja) 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
AU2017376109A1 (en) 2016-12-16 2019-07-11 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
MA50564A (fr) 2017-11-06 2020-09-16 Hutchinson Fred Cancer Res Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
KR102094442B1 (ko) 2018-06-28 2020-03-27 성균관대학교산학협력단 알쯔하이머성 치매의 예방 또는 치료용 물질 및 이를 포함하는 조성물
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6012A (en) * 1849-01-09 Lithographing co
KR100838852B1 (ko) * 2003-09-09 2008-06-16 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
US7211573B2 (en) * 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
JP2008530232A (ja) * 2005-02-15 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 化学療法剤、ｉｌ−２および場合により抗ｃｄ２０抗体の組み合わせを使用してリンパ腫を処置する方法
EP1888051A2 (en) * 2005-05-17 2008-02-20 MERCK SHARP & DOHME LTD. Sulphonamido-substituted cyclohexyl sulphones for treatment of cancer
US20080058316A1 (en) * 2006-02-27 2008-03-06 The Johns Hopkins University Cancer treatment with gama-secretase inhibitors

Also Published As

Publication number Publication date
JP2014221772A (ja) 2014-11-27
US20090181944A1 (en) 2009-07-16
CA2710913A1 (en) 2009-07-16
WO2009087130A1 (en) 2009-07-16
JP2013241443A (ja) 2013-12-05
CR11510A (es) 2010-09-13
EP2244713A1 (en) 2010-11-03
RU2010133489A (ru) 2012-02-20
MA33076B1 (fr) 2012-03-01
TW200936139A (en) 2009-09-01
JP5612482B2 (ja) 2014-10-22
KR20100101624A (ko) 2010-09-17
CN101909633B (zh) 2012-05-30
JP2011509273A (ja) 2011-03-24
CL2009000040A1 (es) 2010-02-12
KR20140007979A (ko) 2014-01-20
IL206361A0 (en) 2010-12-30
AU2009203776A1 (en) 2009-07-16
ZA201004859B (en) 2011-03-30
BRPI0906831A2 (pt) 2019-09-24
CN101909633A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
EA201101507A1 (ru) Способы лечения солидных опухолей
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
AR078588A1 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
CL2009000780A1 (es) Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
MX384721B (es) Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
RU2013121788A (ru) Ингибиторы репликации вич
WO2016133903A3 (en) Combination therapy for cancer treatment
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX2013010770A (es) Tratamiento de tumores solidos.
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
DK1933833T3 (da) Terapi til behandling af overaktiv blære
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor

Legal Events

Date Code Title Description
FB Suspension of granting procedure